Guggenheim, SAB Biotherapeutics hissesini Tip 1 Diyabet potansiyeli nedeniyle Al tavsiyesi ile başlattı
SAB Biotherapeutics stock maintains Buy rating at H.C. Wainwright on positive diabetes treatment data
SAB Biotherapeutics, Inc. (SABS) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release